Astellas Pharma (4503) Investor presentation summary

Strategic vision and growth targets

• Aims for pipeline-led, record-high revenues by mid-2030s, driven by innovation and disciplined cash allocation.

• Focuses on profitable growth, cash generation, and maximizing high-margin Strategic Brands.

• Plans to double Strategic Brands sales by FY2030 compared to FY2025.

• Targets 10+ Phase 3/pivotal studies started by FY2030, with 5+ by FY2027.

• Commits to a minimum annual 2 Yen dividend increase and continued shareholder returns.

Financial performance and outlook

• FY2025 sales revenue reached 2.1T Yen ($14.2B), with a 26% core operating profit margin.

• R&D expenses averaged 291.8B Yen annually (17.2% of revenue) from FY21-25.

• Forecasts 2.2T Yen revenue in FY2026, with a shift to pipeline-led growth from FY2029.

• Strategic Brands expected to contribute over 50% of revenue by FY2030, up from ~23% in FY2025.

• Recurring cost optimization target of 200B Yen for FY26-30 to sustain profitability.

Strategic Brands and pipeline development

• Key Strategic Brands: PADCEV, IZERVAY, VYLOY, VEOZAH, XOSPATA, each with blockbuster potential.

• PADCEV peak sales projected at 400-500B Yen, VYLOY and XOSPATA at 100-200B Yen each.

• Pipeline assets focus on oncology, ophthalmology, and women's health, with major launches expected from FY2029.

• Notable pipeline candidates include setidegrasib (KRAS G12D degrader), ASP2138 (CLDN18.2/CD3 bispecific), and ASP546C (ADC targeting CLDN18.2).

• R&D investment to remain at 20% of revenue, with up to 5% additional for acceleration.